Digital Health Market: Focus on Digital Therapeutics (3rd Edition), 2023-2035: Distribution by Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), Purpose of Solution (Medication Replacement and Medication Augmentation), Type of Business Model (B2B and B2C), Target Therapeutic Area (Cardiovascular Disorders, Chronic Pain, Mental Health Problems, Metabolic Disorders, Neurological Disorders Respiratory Disorders, Sleep Disorders, Substance use Disorders and Other Disorder) and Key Geographical Regions (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035
The global digital therapeutics market is expected to be valued at USD 20 million by 2035 and anticipated to grow at a CAGR of 20% during the forecast period 2023-2035.
Digital Therapeutics (DTx) stands as an increasingly pivotal dimension within the sphere of digital health, offering a direct conduit for dispensing medical interventions targeted at the treatment, management, and prevention of diseases. These solutions pivot on evidence-based and clinically validated software or technologies that capture real-time patient data, thereby heightening the effectiveness of treatments. With the ongoing digital transformation in healthcare, DTx has drawn significant attention from stakeholders and investors within the industry. Concurrently, governmental entities have taken proactive steps, enacting legislation, promulgating laws, and establishing regulations to oversee the burgeoning digital therapeutics sector.
For instance, the US Food and Drug Administration (USFDA) has initiated the Breakthrough Device Designation Program, aimed at expediting approvals for digital therapeutics. Noteworthy is the fact that as of September 2022, around 730 digital health products, spanning digital therapeutics, wellness applications, and digital biomarkers, had secured USFDA approval. Analogously, a parallel trend is observable in other nations like the UK, Germany, Denmark, and South Korea, where regulatory bodies have delineated specific protocols governing digital therapeutics and digital health solutions.
The sustained impetus within this market, coupled with the burgeoning demand for such solutions, is projected to drive market expansion throughout the envisaged forecast period.
Report Coverage
Digital Therapeutics (DTx) stands as an increasingly pivotal dimension within the sphere of digital health, offering a direct conduit for dispensing medical interventions targeted at the treatment, management, and prevention of diseases. These solutions pivot on evidence-based and clinically validated software or technologies that capture real-time patient data, thereby heightening the effectiveness of treatments. With the ongoing digital transformation in healthcare, DTx has drawn significant attention from stakeholders and investors within the industry. Concurrently, governmental entities have taken proactive steps, enacting legislation, promulgating laws, and establishing regulations to oversee the burgeoning digital therapeutics sector.
For instance, the US Food and Drug Administration (USFDA) has initiated the Breakthrough Device Designation Program, aimed at expediting approvals for digital therapeutics. Noteworthy is the fact that as of September 2022, around 730 digital health products, spanning digital therapeutics, wellness applications, and digital biomarkers, had secured USFDA approval. Analogously, a parallel trend is observable in other nations like the UK, Germany, Denmark, and South Korea, where regulatory bodies have delineated specific protocols governing digital therapeutics and digital health solutions.
The sustained impetus within this market, coupled with the burgeoning demand for such solutions, is projected to drive market expansion throughout the envisaged forecast period.
Report Coverage
- The study investigates the digital therapeutics market by examining various aspects such as the type of solution, therapy, purpose, business model, target therapeutic areas, and key geographical regions.
- An analysis of factors impacting market growth, including drivers, restraints, opportunities, and challenges, is conducted within the report.
- Assessment of potential advantages and obstacles within the market is offered, along with insights into the competitive environment for top market players.
- Revenue forecasts for market segments are provided concerning six major regions.
- A comprehensive report covers critical facets of the digital therapeutics market, starting with an introduction to digital therapeutics, elucidating their diverse types, primary healthcare applications, and recent advancements in the field.
- The report delves into the market landscape, categorizing digital therapeutics solutions based on development status, solution types, therapy purposes, targeted indications, therapeutic areas, and involved companies. This includes details such as establishment year, business model, and headquarters location of engaged companies.
- Additionally, the report presents an in-depth analysis of market trends using schematic representations like bubble analysis, tree maps, and world maps, for comparing leading players, distribution across therapeutic areas, and regional presence.
- A competitive analysis evaluates digital therapeutics for popular therapeutic areas, assessing product portfolios and specific parameters such as development status, therapy type, and prescription requirements.
- Company profiles of large, mid-sized, and small players encompass overviews, product portfolios, recent developments, and future outlooks. This includes completed, ongoing, and planned clinical studies, funding analysis, partnership insights, business models, pricing strategies, and market forecasts for the digital therapeutics market until 2035, considering adoption trends, price variations, and market distribution.
- Moreover, a focused evaluation of women's digital health solutions is presented, including developer details, current status, application areas, usage during pregnancy stages, and end-users.
- Finally, the report discusses influential trends, drivers, and challenges employing a SWOT analysis, indicating their relative impact on the digital therapeutics industry.
- Akili Interactive
- Big Health
- Dreem
- Kaia Health
- MindMaze
- Omada Health
- Pear Therapeutics
- Vida Health
- Voluntis
- WellDoc
- Wellthy Therapeutics
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification
3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
3.5.2. Typical Development and Commercialization Path for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Negotiation Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing
3.6 Concluding Remarks
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Indication
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Requirement of Prescription
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution
4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4. Analysis by Location of Headquarters
4.5. Leading Developers: Analysis by Number of Digital Therapeutic Solutions
4.6. Leading Developers: Analysis by Portfolio Strength, Target Indication, and Company Size (4D Bubble Representation)
4.7. Analysis by Therapeutic Area and Company Size (Tree Map Representation)
4.8. Analysis of Regional Activity (World Map Representation)
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameter
5.3. Methodology
5.4. Key Therapeutic Areas
5.4.1. Product Competitive Analysis: Digital Therapeutics Targeting Cardiovascular Disorders
5.4.2. Product Competitive Analysis: Digital Therapeutics Targeting Mental Health Problems
5.4.3. Product Competitive Analysis: Digital Therapeutics Targeting Metabolic Disorders
5.4.4. Product Competitive Analysis: Digital Therapeutics Targeting Neurological Disorders
5.4.5. Product Competitive Analysis: Digital Therapeutics Targeting Substance Use Disorders
5.4.6. Product Competitive Analysis: Digital Therapeutics Targeting Other Therapeutic Areas
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. MindMaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Digital Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Registration Year and Trial Status
7.3.4. Analysis by Trial Phase
7.3.5. Analysis by Type of Study
7.3.6. Analysis by Study Design
7.3.7. Analysis by Study Age
7.3.8. Analysis by Gender of Patients
7.3.9. Analysis of Patients Enrolled by Trial Registration Year
7.3.10. Analysis by Type of Sponsor
7.3.11. Analysis by Focus Area
7.3.12. Analysis by Geography
7.3.13. Analysis by Trial Registration Year, Recruitment Status and Geography
7.3.14. Analysis of Patients Enrolled by Geography
7.4. Clinical End-Points Analysis
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding Models
8.3. Digital therapeutics: List of Funding and Investments
8.3.1. Analysis of Number of Funding Instances by Year of Establishment and Type of Funding
8.3.2. Analysis of Funding Instances by Year
8.3.3. Analysis of Amount Invested by Year
8.3.4. Analysis by Type of Funding
8.3.5. Analysis of Instances and Amount Invested by Type of Therapy
8.3.6. Analysis by Therapeutic Area
8.3.7. Analysis by Geography
8.3.8. Most Active Players: Analysis by Number of Instances
8.3.9. Most Active Players: Analysis by Amount Raised
8.3.10. Most Active Investors: Analysis by Number of Instances
8.4. Concluding Remarks
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Year of Partnership and Type of Partnership
9.3.2.2. Analysis by Type of Partnership and Company Size
9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Year of Partnership and Type of Partner
9.3.3.2. Analysis by Type of Partnership and Type of Partner
9.3.3.3. Analysis by Type of Partner and Company Size
9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Partnership and Type of Therapy
9.3.4.2. Analysis by Type of Partner and Type of Therapy
9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Year of Partnership and Therapeutic Area
9.3.5.2. Analysis by Type of Partner and Therapeutic Area
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.8. Intercontinental and Intracontinental Agreements
10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities through Official Websites
10.2.5. Adoption of Different Business Models
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model
10.2.6. Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks
11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock
11.3. Roots Analysis Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation Hypothesis
11.3.3. Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2022-2035
12.4. Digital Therapeutics Market: Analysis by Type of Solution, 2022-2035
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2022-2035
12.4.2. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and Personal Coach, 2022-2035
12.4.3. Digital Therapeutics Market for Combination Offerings focused on Software Application and Personal Coach, 2022-2035
12.4.4. Digital Therapeutics Market for Combination Offerings focused on Software Application and AI Support, 2022-2035
12.4.5. Digital Therapeutics Market for Combination Offerings focused on Software Application and Device), 2022-2035
12.4.6. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and AI Support), 2022-2035
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2022-2035
12.5. Digital Therapeutics Market: Analysis by Purpose of Solution, 2022-2035
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035
12.6. Digital Therapeutics Market: Analysis by Type of Therapy, 2022-2035
12.6.1. Digital Therapeutics Market for Curative Therapy, 2022-2035
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2022-2035
12.7. Digital Therapeutics Market: Analysis by Business Model, 2022-2035
12.7.1. Digital Therapeutics Market for B2C Model, 2022-2035
12.7.2. Digital Therapeutics Market for B2B Model, 2022-2035
12.8. Digital Therapeutics Market: Analysis by Therapeutic Area, 2022-2035
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035
12.8.2. Digital Therapeutics Market for Chronic Pain, 2022-2035
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2022-2035
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2022-2035
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2022-2035
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2022-2035
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2022-2035
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2022-2035
12.8.9. Digital Therapeutics Market for Other Disorders, 2022-2035
12.9. Digital Therapeutics Market: Analysis by Geography, 2022-2035
12.9.1. Digital Therapeutics Market in North America, 2022-2035
12.9.2. Digital Therapeutics Market in Europe, 2022-2035
12.9.3. Digital Therapeutics Market in Asia, 2022-2035
12.9.4. Digital Therapeutics Market in MENA, 2022-2035
12.9.5. Digital Therapeutics Market in Latin America, 2022-2035
12.9.6. Digital Therapeutics Market in Rest of the World, 2022-2035
12.10. Concluding Remarks
13. WOMEN DIGITAL HEALTH: AN EMERGING NEW CONCEPT
13.1. Introduction: Women Digital Health
13.2. Chapter Overview
13.3. Women’s Digital Health: Product Pipeline
13.3.1. Analysis by Type of Solution
13.3.2. Analysis by Status of Development
13.3.3. Analysis by Product Ratings
13.3.4. Analysis by Application Area
13.3.5. Analysis of Products by Different Stages of Pregnancy
13.3.6. Analysis by Purpose of Solution
13.3.7. Analysis by Type of End-Users
13.3.8. Analysis by Type of Solution and Application Area
13.4. Women’s Digital Health: Developer's Landscape
13.4.1. Analysis by Year of Establishment
13.4.2. Analysis by Company Size
13.4.3. Analysis by Location of Headquarters (Region-wise)
13.4.4. Analysis by Company Size and Region
13.4.5. Analysis by Location of Headquarters (Country-Wise)
13.4.6. Leading Players: Analysis by Number of Solutions
13.4.7. Regional Landscape: Analysis by Type of Solution
14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Comparison of SWOT Factors
14.2.1. Strengths
14.2.2. Weaknesses
14.2.3. Opportunities
14.2.4. Threats
14.2.5. Conclusion
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Ampersand Health
15.2.1. Company Snapshot
15.2.2. Interview Transcript
15.3. Canary Health
15.3.1. Company Snapshot
15.3.2. Interview Transcript
15.4. Dnurse Technology
15.4.1. Company Snapshot
15.4.2. Interview Transcript
15.5. Embr Labs
15.5.1. Company Snapshot
15.5.2. Interview Transcript
15.6. Exosystems
15.6.1. Company Snapshot
15.6.2. Interview Transcript
15.7. Floreo
15.7.1. Company Snapshot
15.7.2. Interview Transcript
15.8. GAIA
15.8.1. Company Snapshot
15.8.2. Interview Transcript
15.9. Healios
15.9.1. Company Snapshot
15.9.2. Interview Transcript
15.10. JOGGO Health
15.10.1. Company Snapshot
15.10.2. Interview Transcript
15.11. metaMe Health
15.11.1. Company Snapshot
15.11.2. Interview Transcript
15.12. SelfBack
15.12.1. Company Snapshot
15.12.2. Interview Transcript
15.13. Somatix
15.13.1. Company Snapshot
15.13.2. Interview Transcript
15.14. Tilak Healthcare
15.14.1. Company Snapshot
15.14.2. Interview Transcript
15.15. Turnaround Health
15.15.1. Company Snapshot
15.15.2. Interview Transcript
15.16. Vida Health
15.16.1. Company Snapshot
15.16.2. Interview Transcript
15.17. Voluntis
15.17.1. Company Snapshot
15.17.2. Interview Transcript
15.18. Wellthy Therapeutics
15.18.1. Company Snapshot
15.18.2. Interview Transcript
15.19. Undisclosed
15.19.1. Interview Transcript: Founder and Chief Executive Officer
16. CONCLUDING REMARKS
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification
3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
3.5.2. Typical Development and Commercialization Path for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Negotiation Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing
3.6 Concluding Remarks
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Indication
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Requirement of Prescription
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution
4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4. Analysis by Location of Headquarters
4.5. Leading Developers: Analysis by Number of Digital Therapeutic Solutions
4.6. Leading Developers: Analysis by Portfolio Strength, Target Indication, and Company Size (4D Bubble Representation)
4.7. Analysis by Therapeutic Area and Company Size (Tree Map Representation)
4.8. Analysis of Regional Activity (World Map Representation)
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameter
5.3. Methodology
5.4. Key Therapeutic Areas
5.4.1. Product Competitive Analysis: Digital Therapeutics Targeting Cardiovascular Disorders
5.4.2. Product Competitive Analysis: Digital Therapeutics Targeting Mental Health Problems
5.4.3. Product Competitive Analysis: Digital Therapeutics Targeting Metabolic Disorders
5.4.4. Product Competitive Analysis: Digital Therapeutics Targeting Neurological Disorders
5.4.5. Product Competitive Analysis: Digital Therapeutics Targeting Substance Use Disorders
5.4.6. Product Competitive Analysis: Digital Therapeutics Targeting Other Therapeutic Areas
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. MindMaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Digital Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Registration Year and Trial Status
7.3.4. Analysis by Trial Phase
7.3.5. Analysis by Type of Study
7.3.6. Analysis by Study Design
7.3.7. Analysis by Study Age
7.3.8. Analysis by Gender of Patients
7.3.9. Analysis of Patients Enrolled by Trial Registration Year
7.3.10. Analysis by Type of Sponsor
7.3.11. Analysis by Focus Area
7.3.12. Analysis by Geography
7.3.13. Analysis by Trial Registration Year, Recruitment Status and Geography
7.3.14. Analysis of Patients Enrolled by Geography
7.4. Clinical End-Points Analysis
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding Models
8.3. Digital therapeutics: List of Funding and Investments
8.3.1. Analysis of Number of Funding Instances by Year of Establishment and Type of Funding
8.3.2. Analysis of Funding Instances by Year
8.3.3. Analysis of Amount Invested by Year
8.3.4. Analysis by Type of Funding
8.3.5. Analysis of Instances and Amount Invested by Type of Therapy
8.3.6. Analysis by Therapeutic Area
8.3.7. Analysis by Geography
8.3.8. Most Active Players: Analysis by Number of Instances
8.3.9. Most Active Players: Analysis by Amount Raised
8.3.10. Most Active Investors: Analysis by Number of Instances
8.4. Concluding Remarks
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Year of Partnership and Type of Partnership
9.3.2.2. Analysis by Type of Partnership and Company Size
9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Year of Partnership and Type of Partner
9.3.3.2. Analysis by Type of Partnership and Type of Partner
9.3.3.3. Analysis by Type of Partner and Company Size
9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Partnership and Type of Therapy
9.3.4.2. Analysis by Type of Partner and Type of Therapy
9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Year of Partnership and Therapeutic Area
9.3.5.2. Analysis by Type of Partner and Therapeutic Area
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.8. Intercontinental and Intracontinental Agreements
10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities through Official Websites
10.2.5. Adoption of Different Business Models
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model
10.2.6. Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks
11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock
11.3. Roots Analysis Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation Hypothesis
11.3.3. Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2022-2035
12.4. Digital Therapeutics Market: Analysis by Type of Solution, 2022-2035
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2022-2035
12.4.2. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and Personal Coach, 2022-2035
12.4.3. Digital Therapeutics Market for Combination Offerings focused on Software Application and Personal Coach, 2022-2035
12.4.4. Digital Therapeutics Market for Combination Offerings focused on Software Application and AI Support, 2022-2035
12.4.5. Digital Therapeutics Market for Combination Offerings focused on Software Application and Device), 2022-2035
12.4.6. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and AI Support), 2022-2035
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2022-2035
12.5. Digital Therapeutics Market: Analysis by Purpose of Solution, 2022-2035
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035
12.6. Digital Therapeutics Market: Analysis by Type of Therapy, 2022-2035
12.6.1. Digital Therapeutics Market for Curative Therapy, 2022-2035
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2022-2035
12.7. Digital Therapeutics Market: Analysis by Business Model, 2022-2035
12.7.1. Digital Therapeutics Market for B2C Model, 2022-2035
12.7.2. Digital Therapeutics Market for B2B Model, 2022-2035
12.8. Digital Therapeutics Market: Analysis by Therapeutic Area, 2022-2035
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035
12.8.2. Digital Therapeutics Market for Chronic Pain, 2022-2035
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2022-2035
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2022-2035
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2022-2035
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2022-2035
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2022-2035
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2022-2035
12.8.9. Digital Therapeutics Market for Other Disorders, 2022-2035
12.9. Digital Therapeutics Market: Analysis by Geography, 2022-2035
12.9.1. Digital Therapeutics Market in North America, 2022-2035
12.9.2. Digital Therapeutics Market in Europe, 2022-2035
12.9.3. Digital Therapeutics Market in Asia, 2022-2035
12.9.4. Digital Therapeutics Market in MENA, 2022-2035
12.9.5. Digital Therapeutics Market in Latin America, 2022-2035
12.9.6. Digital Therapeutics Market in Rest of the World, 2022-2035
12.10. Concluding Remarks
13. WOMEN DIGITAL HEALTH: AN EMERGING NEW CONCEPT
13.1. Introduction: Women Digital Health
13.2. Chapter Overview
13.3. Women’s Digital Health: Product Pipeline
13.3.1. Analysis by Type of Solution
13.3.2. Analysis by Status of Development
13.3.3. Analysis by Product Ratings
13.3.4. Analysis by Application Area
13.3.5. Analysis of Products by Different Stages of Pregnancy
13.3.6. Analysis by Purpose of Solution
13.3.7. Analysis by Type of End-Users
13.3.8. Analysis by Type of Solution and Application Area
13.4. Women’s Digital Health: Developer's Landscape
13.4.1. Analysis by Year of Establishment
13.4.2. Analysis by Company Size
13.4.3. Analysis by Location of Headquarters (Region-wise)
13.4.4. Analysis by Company Size and Region
13.4.5. Analysis by Location of Headquarters (Country-Wise)
13.4.6. Leading Players: Analysis by Number of Solutions
13.4.7. Regional Landscape: Analysis by Type of Solution
14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Comparison of SWOT Factors
14.2.1. Strengths
14.2.2. Weaknesses
14.2.3. Opportunities
14.2.4. Threats
14.2.5. Conclusion
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Ampersand Health
15.2.1. Company Snapshot
15.2.2. Interview Transcript
15.3. Canary Health
15.3.1. Company Snapshot
15.3.2. Interview Transcript
15.4. Dnurse Technology
15.4.1. Company Snapshot
15.4.2. Interview Transcript
15.5. Embr Labs
15.5.1. Company Snapshot
15.5.2. Interview Transcript
15.6. Exosystems
15.6.1. Company Snapshot
15.6.2. Interview Transcript
15.7. Floreo
15.7.1. Company Snapshot
15.7.2. Interview Transcript
15.8. GAIA
15.8.1. Company Snapshot
15.8.2. Interview Transcript
15.9. Healios
15.9.1. Company Snapshot
15.9.2. Interview Transcript
15.10. JOGGO Health
15.10.1. Company Snapshot
15.10.2. Interview Transcript
15.11. metaMe Health
15.11.1. Company Snapshot
15.11.2. Interview Transcript
15.12. SelfBack
15.12.1. Company Snapshot
15.12.2. Interview Transcript
15.13. Somatix
15.13.1. Company Snapshot
15.13.2. Interview Transcript
15.14. Tilak Healthcare
15.14.1. Company Snapshot
15.14.2. Interview Transcript
15.15. Turnaround Health
15.15.1. Company Snapshot
15.15.2. Interview Transcript
15.16. Vida Health
15.16.1. Company Snapshot
15.16.2. Interview Transcript
15.17. Voluntis
15.17.1. Company Snapshot
15.17.2. Interview Transcript
15.18. Wellthy Therapeutics
15.18.1. Company Snapshot
15.18.2. Interview Transcript
15.19. Undisclosed
15.19.1. Interview Transcript: Founder and Chief Executive Officer
16. CONCLUDING REMARKS
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
